Linked Life Data

17876770

Source:http://linkedlifedata.com/resource/pubmed/id/17876770

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17876770rdf:typepubmed:Citationlld:pubmed
pubmed-article:17876770lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17876770lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17876770lifeskim:mentionsumls-concept:C0023473lld:lifeskim
pubmed-article:17876770lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:17876770lifeskim:mentionsumls-concept:C1522577lld:lifeskim
pubmed-article:17876770lifeskim:mentionsumls-concept:C0814128lld:lifeskim
pubmed-article:17876770lifeskim:mentionsumls-concept:C0935989lld:lifeskim
pubmed-article:17876770lifeskim:mentionsumls-concept:C1977882lld:lifeskim
pubmed-article:17876770lifeskim:mentionsumls-concept:C0683598lld:lifeskim
pubmed-article:17876770lifeskim:mentionsumls-concept:C1521828lld:lifeskim
pubmed-article:17876770lifeskim:mentionsumls-concept:C0205251lld:lifeskim
pubmed-article:17876770lifeskim:mentionsumls-concept:C1522326lld:lifeskim
pubmed-article:17876770lifeskim:mentionsumls-concept:C0205087lld:lifeskim
pubmed-article:17876770lifeskim:mentionsumls-concept:C0457343lld:lifeskim
pubmed-article:17876770pubmed:issue3lld:pubmed
pubmed-article:17876770pubmed:dateCreated2008-2-4lld:pubmed
pubmed-article:17876770pubmed:abstractTextThe introduction of Imatinib (IM) has significantly altered the treatment for CML, although only limited follow-up results are available. As failure of Interferon-alpha had been associated with poor prognosis and results of IM-treatment in this patient group may allow earlier estimation of long-term benefits for early chronic phase patients. Therefore we prospectively analyzed the quality and duration of remissions and the rate of BCR-ABL resistance mutations occurring in patients treated with IM, if they were intolerant or refractory to interferon. Fifty-nine patients were included and median follow up is 4.75 years. Haematologic remission rate was 92% and 62% of patients achieved at least major cytogenetic remission. There were no major differences between patients failing or being refractory to IFN. Major molecular response was observed in 67% of patients evaluable. For the entire group, median PFS was 4.3 years and OS was 82% at 4.75 years. Haematologic and complete cytogenetic remissions, but not molecular responses were correlated with improved PFS and OS. In patients with progression or inadequate response, BCR-ABL kinase domain mutations were detected in 3/28 patients. IM resulted in prolonged remission rates in a substantial proportion after IFN-failure/intolerance, with no differences in these patient groups. Quality of hematologic and cytogenetic, but not molecular response was associated with duration of remissions and survival. A low rate of resistance-mutations was detected, suggesting that alternative mechanism may play an important role in disease progression.lld:pubmed
pubmed-article:17876770pubmed:languageenglld:pubmed
pubmed-article:17876770pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17876770pubmed:citationSubsetIMlld:pubmed
pubmed-article:17876770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17876770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17876770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17876770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17876770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17876770pubmed:statusMEDLINElld:pubmed
pubmed-article:17876770pubmed:monthMarlld:pubmed
pubmed-article:17876770pubmed:issn0361-8609lld:pubmed
pubmed-article:17876770pubmed:authorpubmed-author:MeyerRalf GRGlld:pubmed
pubmed-article:17876770pubmed:authorpubmed-author:HuberChristop...lld:pubmed
pubmed-article:17876770pubmed:authorpubmed-author:HessGeorgGlld:pubmed
pubmed-article:17876770pubmed:authorpubmed-author:SchuchBrigitt...lld:pubmed
pubmed-article:17876770pubmed:authorpubmed-author:BechtholdKatj...lld:pubmed
pubmed-article:17876770pubmed:authorpubmed-author:El-KholyIlseIlld:pubmed
pubmed-article:17876770pubmed:copyrightInfo(c) 2007 Wiley-Liss, Inc.lld:pubmed
pubmed-article:17876770pubmed:issnTypePrintlld:pubmed
pubmed-article:17876770pubmed:volume83lld:pubmed
pubmed-article:17876770pubmed:ownerNLMlld:pubmed
pubmed-article:17876770pubmed:authorsCompleteYlld:pubmed
pubmed-article:17876770pubmed:pagination178-84lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:meshHeadingpubmed-meshheading:17876770...lld:pubmed
pubmed-article:17876770pubmed:year2008lld:pubmed
pubmed-article:17876770pubmed:articleTitleSustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.lld:pubmed
pubmed-article:17876770pubmed:affiliationDepartment of Haematology/Oncology, Johannes Gutenberg-University, Mainz, Germany. g.hess@3-med.klinik.uni-mainz.delld:pubmed
pubmed-article:17876770pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17876770lld:pubmed